Jazz Pharmaceuticals plc
JAZZ
$244.96
-$0.89-0.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 12.59% | 9.20% | 4.88% | 4.13% | 4.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.59% | 9.20% | 4.88% | 4.13% | 4.52% |
| Cost of Revenue | 15.57% | 17.45% | 14.20% | 13.18% | 11.33% |
| Gross Profit | 12.27% | 8.33% | 3.92% | 3.23% | 3.84% |
| SG&A Expenses | -3.65% | -4.39% | 17.96% | 20.00% | 17.61% |
| Depreciation & Amortization | 7.51% | 7.43% | 4.35% | 3.84% | 2.51% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.37% | -0.22% | 6.90% | 9.05% | 6.38% |
| Operating Income | 68.38% | 57.35% | -3.42% | -15.48% | -3.83% |
| Income Before Tax | 242.01% | -160.63% | -234.12% | -277.48% | -273.26% |
| Income Tax Expenses | -98.48% | -105.60% | -198.00% | -403.46% | -8.26% |
| Earnings from Continuing Operations | 332.38% | -93.89% | -163.58% | -179.56% | -202.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 332.38% | -93.89% | -163.58% | -179.56% | -202.51% |
| EBIT | 68.38% | 57.35% | -3.42% | -15.48% | -3.83% |
| EBITDA | 37.84% | 32.62% | 0.61% | -6.15% | -0.22% |
| EPS Basic | 331.28% | -94.00% | -163.50% | -179.93% | -205.10% |
| Normalized Basic EPS | 135.87% | 129.93% | 5.08% | -12.90% | 6.63% |
| EPS Diluted | 315.33% | -100.31% | -167.99% | -185.53% | -215.64% |
| Normalized Diluted EPS | 127.12% | 133.48% | 6.80% | -7.85% | 15.71% |
| Average Basic Shares Outstanding | 1.11% | -0.40% | -1.38% | -2.40% | -2.77% |
| Average Diluted Shares Outstanding | 5.53% | -1.16% | -3.74% | -7.43% | -9.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |